FDA approves Teva's generic injection for iron intoxication

By Lisa Kerner

Erie, Pa., April 3 - Teva Pharmaceutical Industries Ltd. said the Food and Drug Administration has granted approval for its Abbreviated New Drug Application for Deferoxamine Mesylate for injection USP (500 mg/vial and 2 g/vial), the AP-rated generic equivalent of Novartis' Desferal for injection for acute treatment of iron intoxication and chronic iron overload.

Total annual sales of Deferoxamine Mesylate for injection are approximately $43 million, according to a company news release.

Shipment of this product will begin immediately, Teva said.

Teva is a generic pharmaceutical company based in Petach Tikva, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.